BioFocus is tasked with performing medicinal and computational chemistry as well as supporting biology and ADMET services.

BioFocus DPI entered into a drug discovery collaboration with AstraZeneca. This is the second program between the two companies after the August 2006 agreement.

In this new deal, BioFocus DPI will perform medicinal chemistry, computational chemistry, and supporting biology and ADME-Tox services for an AstraZeneca drug discovery program. Total contract value for Galapagos is Euro 620,000.

“We have been pleased with the level of progress thus far and expect that BioFocus DPI’s expanded ADMET and predictive drug discovery capabilities will be key contributors in advancing this hit-to-lead program,” says Lars-Erik Arvidsson, vp, head of respiratory research, AstraZeneca R&D Lund.

Next articleProBioGen and Minapharm Ink Development and Co-Promotion Agreements